Industry committee  Good morning. Thank you so much, Madam Chair, and thank you to the committee for inviting us today. I'm really honoured to be with you today as the co-chair of Canada's vaccine task force. I think I speak for my colleague, Mark Lievonen, who is here, and all task force members

Industry committee  I could start on that, Madam Chair. As we looked at the candidates from a vaccine point of view, there are some vaccine platforms that have been used in programs since the 1950s when we started to roll out public health programs, so we would have a lot more experience and knowle

Industry committee  We had a process in place whereby potential interests were categorized under nine categories, then the impacts of those potential interests were considered by the secretariat. We were overly disclosing any potential interest. Normally you would disclose something involving an i

Industry committee  Yes, there were. There were, I think, 29 or 30 instances in which people recused themselves.

Industry committee  I would say that we looked at all the international candidates on the same shelf. CanSino was one of those international candidates. We were hoping for a domestic candidate and we very much placed equal emphasis on all the domestic candidates, but ultimately our goal was a safe a

Industry committee  There were at least 24 SIF proposals, but there were other ways that support could be accessed. Mark?

Industry committee  Every possible candidate was explored, and AstraZeneca was one of them. Our current option is to get it through COVAX. Perhaps Mark or Roger could speak further to the AstraZeneca option.

Industry committee  I'm not getting translation, but you related the timelines for the pandemic and asked who made the decision about the task force and who they consulted. I think that would be a question for the secretariat. Would that be correct, Roger?

Industry committee  I can speak to the question about me. Roger, perhaps, could do the second part. You're right that it's very similar to what we do for journals. For every trial that we publish the results for, for every talk that we give, particularly in a university, we have to have a slide tha

Industry committee  I can tell you what the disclosure was to the NRC. I listed every possible relationship I would have had to Janssen. Not all of those would have been listed, potentially.

Industry committee  No, journals are very different, so you can't make a general statement about journals, I think it would be fair to say.

Industry committee  Thank you for the opportunity to clarify that. I would separate quite clearly clinical development and research from choosing vaccines to buy for Canada. We do here at the Canadian Center for Vaccinology at Dalhousie a number of very early vaccine studies. Most of those never ma

Industry committee  Providence would have been considered along with all the domestic candidates. A very systematic and similar process was considered for each one. They submitted an application, so we had the application to look at. We had interviews where they came before the committee and made pr

Industry committee  Okay. I'm so sorry.

Industry committee  I think you're asking whether in my work at the Canadian Center for Vaccinology we had discussions with AstraZeneca. We are certainly very aware of the group at Oxford and collaborate with them, but they were not looking for a partnership with us to do studies—